0000000000733445

AUTHOR

G.c. Isaia

showing 4 related works from this author

Prevalence of hypovitaminosis D in elderly women in Italy: clinical consequences and risk factors

2002

In order to evaluate the prevalence, risk factors, and clinical consequences of hypovitaminosis D in elderly Italian women a multicenter study of 43 osteoporosis centers from all regions of Italy was carried out. Study population included 700 women aged 60-80 years in whom blood was taken for 25-hydroxyvitamin D (25OHD) and parathyroid hormone (PTH) measurements. All subjects were also questioned to assess the prevalence of several risk factors for hypovitaminosis D, osteoporotic fractures and activities of daily living (ADL). Values of 25OHD lower than 5 ng/ml were found in 27% of the women and lower than 12 ng/ml in 76%. 25OHD and PTH levels were negatively correlated ( r=-0.38, after log…

medicine.medical_specialtyActivities of daily livingEndocrinology Diabetes and MetabolismOsteoporosisPopulationvitamin D deficiencyRisk FactorsPrevalencemedicineVitamin D and neurologyHumansRisk factoreducationAged25-Hydroxyvitamin D 2Aged 80 and overHip fractureeducation.field_of_studybusiness.industrySmokingMiddle AgedVitamin D Deficiencymedicine.diseaseDietItalyParathyroid HormonePhysical therapyEducational StatusPopulation studyFemaleDairy ProductsbusinessDemographyOsteoporosis International
researchProduct

Two novel mutations at exon 8 of the Sequestosome 1 (SQSTM1) gene in an Italian series of patients affected by Paget's disease of bone (PDB).

2003

PDB is genetically heterogeneous. Mutations of the sequestosome1 gene have been reported in sporadic and familial forms of Paget's in patients of French Canadian and British descent. Mutational analyses in different ethnic groups are needed to accurately investigate hereditary diseases. We describe two novel mutations of sequestosome1 in 62 Italian sporadic patients, confirming the role of the encoded protein in this disorder. Introduction: Paget's disease of bone (PDB) is a relatively common disease of bone metabolism reported to affect up to 3% of whites over 55 years of age. The disorder is genetically heterogeneous, and at present, there is scientific evidence that at least eight differ…

AdultMaleEndocrinology Diabetes and MetabolismPopulationExonSequestosome 1GenotypeSequestosome-1 ProteinmedicineHumansOrthopedics and Sports MedicineeducationAdaptor Proteins Signal TransducingAgedDNA PrimersGeneticsAged 80 and overeducation.field_of_studyBase SequenceGenetic heterogeneitybusiness.industryProteinsExonsMiddle Agedmedicine.diseaseOsteitis DeformansPenetrancePaget's disease of boneHereditary DiseasesMutationFemalebusinessJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
researchProduct

Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis.

1992

Recently it has been demonstrated that ipriflavone (IP), an isoflavone derivative, is able to increase bone mass in patients with established postmenopausal osteoporosis (PMO). Here we present a preliminary report of a 2-year multicenter, double-blind, placebo-controlled clinical study performed in order to evaluate the efficacy and tolerability of IP in PMO. A large number of patients with PMO, referred to 12 Italian centers, was randomly divided into 2 groups and treated with oral IP (600 mg/day) or placebo (Pl). All patients received an oral Ca supplement (1 g/day). One hundred and twenty six patients completed 1 year of the study. Bone mineral density (BMD) of the distal radius, measure…

medicine.medical_specialtyUrinary systemOsteoporosisUrologyPlaceboBiochemistryExcretionEndocrinologyDouble-Blind MethodBone DensityInternal medicinemedicineHumansOsteoporosis PostmenopausalAgedBone mineralCalcium metabolismbusiness.industryMiddle Agedmedicine.diseaseIsoflavonesEndocrinologyItalyTolerabilityCalciumFemaleSurgeryIpriflavonebusinessmedicine.drug
researchProduct

Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.

1997

Two hundred and fifty-five postmenopausal women with distal forearm bone mineral density (BMD) 1 SD below the mean value for normal age-matched postmenopausal subjects were randomly allocated to a 2-year treatment with oral ipriflavone (200 mg t.i.d.) or a matched placebo, according to a double-masked, parallel-group design. All patients also received a 1 g/day calcium supplement. Distal radius BMD and bone metabolism markers were measured at baseline, and every 6 months. Blood haematology and chemistry and physical parameters were monitored at the same time. One hundred and ninety-six patients completed 2 years of treatment. BMD changes from baseline were analysed according to valid comple…

medicine.medical_specialtyBone diseaseEndocrinology Diabetes and MetabolismOsteoporosisUrologyPlaceboBone and BonesBone remodelingchemistry.chemical_compoundBone DensityHumansMedicineOsteoporosis PostmenopausalAgedBone mineralCreatinineIntention-to-treat analysisbusiness.industryMiddle Agedmedicine.diseaseIsoflavonesSurgeryHydroxyprolineRadiuschemistryFemaleIpriflavonebusinessmedicine.drug
researchProduct